Promising new experimental combination therapy in Hypoxic Ischemic Injury

In a study published in Neonatology on Oct. 13, 2017, researchers from George Washington University, Washington, DC using newborn piglet models exposed to hypoxia-ischemia studied the ffect of standard cooling therapy (therapeutic hypothermia) alone and in combination with a selective Src kinase inhibitor, PP2, that blocks a regulatory enzyme of apoptosis (cell death). PP2 is a substance that has frequently been used in cancer research as a "selective" inhibitor for Src-family kinases. This stud...
Continue reading

Dietary supplement Glucosamine may have a role in reducing excitability in brain cells

glucosamine
In an article published in the Journal of Neuroscience Prof. John Chatham, of the Department of Pathology at the University of Alabama at Birmingham, and colleagues report that increasing O-GlcNAcylation levels in brain cells using the dietary supplement "glucosamine" widely used as a supplement to help reduce pain in osteoarthritis and other conditions was found to reduce  reduce neural excitability in rodents. The researchers had in a previous study shown that increases in prote...
Continue reading

Circadian Rhythm Protein CLOCK linked to severe epilepsy

clockandepilepsy
In new research published in Neuron this week researchers from Brown University in Providence, RI suggests that disruption of  the circadian rhythm protein CLOCK alters cortical circuits and may lead to generation of focal epilepsy.  Dr. Liu and her colleagues used resected brain tissue from epilepsy surgery for focal cortical dyplasias and analysed the  tissue's transcriptome, or a survey of the messenger RNA (mRNA) in any given population of cells. They ...
Continue reading

Ataluren shows promise for muscular dystrophy in phase 3 clinical trial

m1_s2_03_03_01_step3-720x400

In a paper just published online in the journal The Lancet , Craig McDonald and colleagues at 53 study sites in 18 countries describe the clinical benefit of using the drug ataluren for a certain group of patients carrying a specific "nonsense mutation" for Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is a progressive and life-limiting X-linked recessive disorder caused by mutations in the DMD gene that result in reduced or absent dystrophin production. Dystrophin is part of th...
Continue reading

ICNA Future Leaders Programme

unname_20170712-113447_1
  At the Amsterdam ICNC in May 2016 interested members of the ICNA met to discuss a way forward to provide support for trainees and newly qualified child neurologists (within 5 years) Summary of key points raised at this meeting were: Education Direction of how to learn and what to learn for trainees Educational meetings – especially focused on-site educational meetings Research How to put a grant together (Plan a symposium at the next ICNC2018 on this) Training Support from the EB with gui...
Continue reading